En Es
Categories

Industry News

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

By Labmedica International staff writers
13 Jan 2021

Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine the best treatment strategy for each patient.

The image analysis algorithms use artificial intelligence (AI) to support pathologists in making faster, more accurate patient diagnoses in breast cancer. A mutation in the HER2 gene, which occurs in as many as 20% of the 2.1 million cases of breast cancer diagnosed globally each year, is responsible for aggressive growth in some patients. Identifying this mutation is important in determining which patients may benefit from targeted treatment. uPath HER2 (4B5) image analysis for breast cancer helps pathologists to quickly determine whether tumors are positive for the HER2 biomarker, highlighting positively stained tumor cell membranes with a clear visual overlay for easy reference.

uPath HER2 Dual ISH image analysis for breast cancer assists the pathologist in the determination of HER2 gene amplification. A heatmap is provided to guide pathologists to areas of interest where the algorithm can identify cells to inform the determination of a treatment strategy. Validated on the VENTANA HER2 (4B5) assay and the VENTANA HER2 Dual ISH DNA Probe Cocktail, the algorithms are ready-to-use and integrated within the Roche uPath enterprise software.

The uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis algorithms for breast cancer expand Roche’s digital pathology portfolio to empower precision diagnosis. The uPath image analysis algorithm suite for pathology decision support offers ready-to-use image analysis tools, providing fast, consistent and automated analysis so that pathologists can quickly, accurately and confidently assess immunohistochemistry and in situ hybridization. All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche Tissue Diagnostics assay.

“About 15 to 20% of women diagnosed with breast cancer are HER2 positive, which makes fast and accurate diagnosis critical,” said Thomas Schinecker, CEO Roche Diagnostics. “Roche is continuing to innovate in HER2 diagnostics by providing precise information through image analysis algorithms for pathology decision support.”






E-mail Print
FaceBook Twitter Google+ Linked in

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests
More info

More articles about Roche Diagnostics

26 Jan 2021
Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions
Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment to their long standing Distribution, Sales and Service (DSS) agreement, allowing Roche to continue to distribute Sysmex hematology products, including instruments and reagents.
Read More
18 Oct 2018
Roche Launches Roche Healthcare Consulting
Roche (Basel, Switzerland) has launched Roche Healthcare Consulting, a specialized consulting service that aims to help leaders in laboratories, hospitals and other healthcare groups optimize their operational, clinical and financial performance.
Read More

Additional news

25 Jan 2021
Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer
Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability.
Read More
21 Jan 2021
New AI-Based Image Analysis Platform Enables Physicians to Analyze CT and MRI Scans in Half the Time of Traditional Methods
The US Food and Drug Administration (FDA) has granted 510(k) clearance for a new image analysis platform that enables physicians to analyze CT and MRI scans in half the time of traditional methods.
Read More
21 Jan 2021
New AI-Based Medical Image Segmentation and Measurement Tool Minimizes Human Errors in Clinical Analysis
A new general purpose, AI-based medical image segmentation and measurement tool for detecting objects of interest and their boundaries quickly and automatically could make surgical and diagnostic measurements easier and more accurate for better treatment decisions.
Read More
20 Jan 2021
Deep Learning Outperforms Standard Machine Learning at Brain Imaging Analysis, Finds New Study
Compared to standard machine learning models, deep learning models are largely superior at discerning patterns and discriminative features in brain imaging, despite being more complex in their architecture, according to a new study.
Read More
20 Jan 2021
Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD 450 million in cash.
Read More
20 Jan 2021
Hillrom Acquires Bardy Diagnostics to Expand into Ambulatory Cardiac Monitoring Segment
Hillrom (Chicago, IL, USA) has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx; Seattle, WA, USA) for a cash consideration of USD 375 million.
Read More
20 Jan 2021
Philips Acquires Capsule Technologies to Expand Leadership in Patient Care Management Solutions for Hospitals
Royal Philips (Amsterdam, the Netherlands) has signed an agreement to acquire Capsule Technologies, Inc. (Andover, MA, USA), a provider of medical device integration and data technologies for hospitals and healthcare organizations.
Read More
19 Jan 2021
Artificial Intelligence Add-On for `World’s First` Portable MR Imaging System Receives FDA Clearance
Hyperfine Research, Inc. (Guilford, CT, USA) has received 510(k) clearance from the US FDA for its deep-learning image analysis software that measure brain structure and pathology in images acquired by the Swoop Portable MR Imaging System.
Read More
14 Jan 2021
Cutting-Edge AI Software Automatically Analyzes Screening Mammograms to Accurately Diagnose Breast Cancer Much Earlier
A cutting-edge artificial intelligence (AI) solution assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions